# Myriad Genetics account plan

> Myriad Genetics is a Salt Lake City molecular diagnostics company with $824.5 million FY2025 revenue in cancer, mental health and prenatal testing.

## At a glance

Myriad Genetics is a molecular diagnostics and precision medicine company headquartered in Salt Lake City, Utah, selling genetic tests to healthcare providers and health systems, paid by commercial payors, Medicare and patients. It sells mainly in the United States (U.S. revenue $768.0 million of $824.5 million in 2025) and Japan. FY2025 revenue fell 2% to $824.5 million on 1,537 thousand tests, and the net loss was $365.9 million, driven by $319.4 million of impairment charges. It had about 2,700 full-time equivalent employees at December 31, 2025. In October 2026 it agreed to sell its Prenatal Health business to Labcorp to focus on the Cancer Care Continuum and Mental Health.

## Business units

- **Cancer Care Continuum** (61% of Q3 2026 revenue ($123.9 million)): Hereditary cancer and tumor tests: MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris + AI, Precise Tumor and Precise MRD, formerly reported as Hereditary Cancer ($372.4 million in 2025) and Tumor Profiling ($121.7 million). Q3 2026 volume rose 4% to 98 thousand tests, but revenue per test fell 9% over nine months, mainly on lower reimbursement. Precise MRD reimbursement in breast cancer is expected in H1 2027.
- **Mental Health** (20% of Q3 2026 revenue ($39.5 million)): The GeneSight Psychotropic pharmacogenomic test, run in Mason, Ohio and sold only in the U.S. Revenue fell 15% in 2025 to $144.1 million after UnitedHealthcare stopped covering GeneSight, then grew 7% over the first nine months of 2026 to $114.6 million; over 40,000 clinicians ordered in Q3 2026.
- **Prenatal Health** (19% of Q3 2026 revenue ($39.3 million)): Foresight carrier screen, Prequel prenatal screen, FirstGene and SneakPeek, sold in the U.S. Q3 2026 volume fell 11% to 138 thousand tests. The business is to be sold to Labcorp for $210 million cash plus inventory, with closing expected by early 2027.

## Strategic priorities

- **Build the Cancer Care Continuum menu**: Build a comprehensive test menu for the Cancer Care Continuum, prioritising high-growth applications such as Precise MRD; R&D investment is expected to increase in 2026 with a CCC focus.
- **Exit Prenatal Health**: Sell Prenatal Health to Labcorp for $210 million cash plus inventory; management expects revenue growth to improve by over 100 basis points and gross margin by more than 500 basis points after the sale.
- **Grow Mental Health at or above market**: Expand GeneSight with primary care and behavioral health clinicians, state biomarker laws and patient direct-payment options.
- **Restore profitable growth**: The Ascend programme, run with a leading consulting firm, modernises processes, organisation and tools; management expects "meaningful progress in 2027" on profitability.
- **Push back on reimbursement pressure**: Process improvements, "AI-enabled workflow acceleration" and a payer-by-payer market access strategy against rising denials in hereditary cancer testing.

## Latest results

Q3 2026 revenue was $202.7 million, +6% sequentially and -1% year-over-year, as average revenue per test rose 7% sequentially while volume fell 2% year-over-year. Cancer Care Continuum revenue was $123.9 million (+1%) and GeneSight $39.5 million (+2%), while Prenatal Health fell 12% to $39.3 million. Gross margin was 67.9%, down 200 basis points, and the net loss widened to $43.9 million from $27.4 million; adjusted EBITDA was -$5.3 million. FY2026 revenue guidance was raised at the mid-point to $780-$790 million, of which Cancer Care Continuum and Mental Health $620-$630 million. Cash was $107.1 million at September 30, 2026.

## Investments and deals

- **Prenatal Health divestiture**: Definitive agreement of October 19, 2026 to sell Prenatal Health to Labcorp for $210 million cash plus inventory; proceeds may repay part or all of the OrbiMed loans, fund operations and invest in the Cancer Care Continuum.
- **OrbiMed term loan**: July 2025 facility of $200.0 million, $125.0 million drawn, maturing July 2030, with a minimum trailing revenue covenant starting at $615.0 million.
- **Oncology partnerships**: Exclusive U.S. rights to PATHOMIQ's AI prostate platform (Prolaris + AI launched mid-2026), a September 2025 liquid biopsy companion diagnostic collaboration with SOPHiA GENETICS, and an October 2026 SOPHiA GENETICS collaboration on a prostate genomic instability score with AstraZeneca.
- **Commercial organisation**: Sales and marketing expense rose 18% to $83.9 million in Q3 2026, including $10.6 million more personnel cost from investment in the commercial organisation.
- **Ascend programme**: A multi-year initiative with a leading consulting firm to modernise processes, organisation and tools, with more detail promised in 2027.

## Challenges and risks

- **Reimbursement pressure**: Hereditary cancer revenue per test is down on denials; management frames long-term per-test declines "of 1% to 5%, maybe skewing 3% to 5% most recently".
- **GeneSight coverage loss**: UnitedHealthcare stopped covering GeneSight under its commercial, individual exchange and certain managed Medicaid plans, cutting Mental Health revenue 15% in 2025.
- **Losses and liquidity**: Nine-month 2026 net loss of $121.2 million, an operating cash outflow of $30.5 million, and cash down to $107.1 million from $149.6 million, with a $125.0 million term loan at 10.2%.
- **Competition**: Natera, Labcorp, Quest, Tempus, Guardant and others compete in oncology, women's health and mental health testing.
- **Single-site operations**: Each test is processed in a single laboratory, with limited or single-source suppliers.

## What leadership says

> "continued softness in our Prenatal Health business, reimbursement pressure on HCT and financial stability" — Sam Raha, President and Chief Executive Officer, Q3 2026 earnings call, November 4, 2026, naming the three challenges

> "a decisive step to support our strategic intent to increase profitable growth by focusing on the Cancer Care Continuum" — Sam Raha, President and Chief Executive Officer, Q3 2026 earnings release, November 4, 2026, on the Prenatal Health sale

> "it has become increasingly clear that our prenatal testing business was unable to generate attractive returns in the near term" — Ben Wheeler, Chief Financial Officer, Q3 2026 earnings call, November 4, 2026

> "quite frankly, we haven't lived up to our potential" — Sam Raha, President and Chief Executive Officer, Mendelspod podcast, September 16, 2025


## Where a supplier can help

- **Revenue cycle and denial management**: Reimbursement pressure from denials and the AI-enabled workflow and payer-by-payer access work make revenue cycle, appeals automation and market access services relevant.
- **Operating model modernisation**: The Ascend programme to modernise processes, organisation and tools is a direct opening for process, workflow and productivity software.
- **Divestiture separation**: The Prenatal Health sale to Labcorp, with about 500 employees moving, requires carve-out, systems separation and transition services.
- **Oncology commercial build-out**: Investment in the commercial organisation and Precise MRD launches call for sales enablement, EMR integration and physician education support.
- **Cost discipline**: Losses and a shrinking cash balance under a revenue covenant favour suppliers that lower laboratory and operating cost.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Myriad Genetics Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/899923/000089992326000018/mygn-20251231.htm)

Annual report · 2026-02-24

- Myriad Genetics is a Salt Lake City molecular diagnostics and precision medicine company selling genetic tests in oncology, women's health and mental health, mainly in the United States (U.S. revenue $768.0 million of $824.5 million in 2025) and Japan.
- FY2025 revenue fell 2% to $824.5 million while test volume rose about 1% to 1,537 thousand tests; net loss was $365.9 million ($3.95 per share), driven by $319.4 million of goodwill and long-lived asset impairment charges on the Women's Health and Mental Health reporting units.
- Revenue mix: Hereditary Cancer $372.4 million (45%), Prenatal $186.3 million (23%), Mental Health $144.1 million (17%), Tumor Profiling $121.7 million (15%). The company reports a single operating segment.
- Mental Health revenue dropped 15% ($26.1 million) after UnitedHealthcare stopped covering the GeneSight test under its commercial, individual exchange and certain managed Medicaid plans; the company expects this to keep weighing on revenue.
- Strategy: accelerate profitable growth by (i) building a comprehensive test menu for the Cancer Care Continuum (CCC), prioritising high-growth applications such as Precise MRD, (ii) growing Prenatal Health and Mental Health at or above market, (iii) financial and operational discipline; R&D investment is expected to increase in 2026 with a CCC focus.
- Partnerships: exclusive U.S. rights to PATHOMIQ's AI platform for prostate cancer (AI test launch expected H1 2026) and a September 2025 collaboration with SOPHiA GENETICS on a global liquid biopsy companion diagnostic.
- Balance sheet: $149.6 million cash at end-2025; new OrbiMed term loan facility of $200.0 million ($125.0 million drawn, maturing July 2030, 10.4% rate at year-end) with a minimum trailing revenue covenant starting at $615.0 million.
- New leadership in 2025: Samraat (Sam) Raha CEO from April 30, 2025, Mark Verratti COO, Brian Donnelly Chief Commercial Officer, Benjamin R. Wheeler CFO from August 16, 2025; about 2,700 FTE employees.
- Key risks: payer coverage and reimbursement (Medicare about 13% of revenue), ability to reach profitability, debt covenants, single-site processing of each test, competition from Natera, Labcorp, Quest, Tempus, Guardant and others.

### [Myriad Genetics Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/899923/000162828026071767/mygn-20260930.htm)

Interim report · 2026-11-06

- Q3 2026 revenue $202.7 million (vs $205.7 million); nine-month revenue $593.8 million (vs $614.7 million).
- Revenue is now reported in three categories: Cancer Care Continuum (CCC) $123.9 million in Q3 (61%), Mental Health $39.5 million (20%), Prenatal Health $39.3 million (19%).
- Q3 volume: CCC 98 thousand tests (+4%), Mental Health 141 thousand (+3%), Prenatal Health 138 thousand (-11%). Over nine months CCC revenue per test fell 9%, mainly lower reimbursement.
- On October 19, 2026 Myriad agreed to sell its Prenatal Health business (Foresight, Prequel, FirstGene, SneakPeek) to Laboratory Corporation of America for $210 million cash plus inventory, expected to close by early 2027; proceeds may repay part or all of the OrbiMed loans, fund operations and invest in CCC.
- Sales and marketing expense rose 18% to $83.9 million in Q3 (41.4% of revenue), including $10.6 million more personnel cost from investment in the commercial organisation.
- Cash and cash equivalents $107.1 million at September 30, 2026 (from $149.6 million); nine-month operating cash outflow $30.5 million; $125.0 million term loan at 10.2%.
- Strategy restated: CCC test menu, Mental Health growth at or above market, and profitable growth; Prenatal Health no longer a growth pillar.
- New risk factors: the sale may not close (termination date February 19, 2027, extendable to October 19, 2027; $10.5 million fee payable by the buyer if regulatory clearances fail).

### [Myriad Genetics reports third quarter 2026 financial results (earnings release)](https://www.sec.gov/Archives/edgar/data/899923/000162828026070135/ex991mygn-xearningsrelease.htm)

Interim report · 2026-11-04

- Q3 2026 revenue $202.7 million, +6% sequentially and -1% year-over-year; average revenue per test +7% sequentially and +1% year-over-year; test volume -1% and -2%.
- Cancer Care Continuum and Mental Health volume +3% to 239,000 tests; Prenatal Health volume -11% to 138,000 tests.
- Gross margin 67.9%, down 200 basis points; operating loss $39.9 million; net loss $43.9 million ($0.46 per share); adjusted EBITDA -$5.3 million (vs +$10.3 million).
- Hereditary cancer testing revenue -1% on lower reimbursement, volume +6%; average revenue per hereditary cancer test improved 9% over Q2 2026.
- GeneSight revenue $39.5 million (+2%); Prenatal Health revenue $39.3 million (-12%), to be sold to Labcorp for $210 million cash plus inventory, closing expected by early 2027.
- FY2026 guidance: revenue $780-$790 million (mid-point raised), of which Cancer Care Continuum and Mental Health $620-$630 million and Prenatal Health about $160 million; adjusted gross margin 66%-67%.
- Cash $107.1 million; adjusted free cash flow $1.6 million in the quarter.
- CEO Sam Raha: the sale is "a decisive step" to focus on the Cancer Care Continuum, "including screening, treatment selection and monitoring along with remission surveillance".

### [Myriad Genetics Q3 2026 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/11/05/myriad-genetics-mygn-q3-2026-earnings-call-transcript/)

Executive talk · Sam Raha, President and Chief Executive Officer · 2026-11-05

- CEO Sam Raha framed the quarter around three challenges, "continued softness in our Prenatal Health business, reimbursement pressure on HCT and financial stability", and the actions taken: portfolio review, reimbursement initiatives, the Ascend operating-model programme and tighter execution.
- The Prenatal Health sale to Labcorp ($210 million plus inventory, about 1.3x trailing revenue) is called "transformational" by CFO Ben Wheeler; about 500 employees move to Labcorp.
- After the sale, management expects revenue growth to improve by over 100 basis points and gross margin by more than 500 basis points, with "meaningful progress in 2027" on bottom-line profitability.
- Hereditary cancer testing (HCT): volume +6%, unaffected-patient volume at a three-year high; revenue per test softness comes from denials ("0 pay"), not contract changes; long-term per-test decline framed as 1% to 5% a year.
- Precise MRD: in MONSTAR-3 interim data 91% of patients who recurred were MRD-positive one month after surgery; breast cancer reimbursement expected in H1 2027, colorectal and renal later in 2027.
- GeneSight reached over 40,000 ordering clinicians in the quarter; Prolaris volume hurt by an NCCN guideline favouring blood biomarkers and imaging before biopsy.
- Ascend: a multi-year initiative with a leading consulting firm to modernise processes, organisation and tools; more detail promised in 2027.
- Use of proceeds: some debt repayment, internal and external growth investments (including MRD) and operations; about $182 million of available capital at quarter end.

### [Myriad's Next Chapter: New CEO Sam Raha on Growth, AI, and MRD Testing (Mendelspod)](https://www.mendelspod.com/p/myriads-next-chapter-new-ceo-sam)

Podcast · Sam Raha, President and Chief Executive Officer · 2025-09-16

- First interview of Sam Raha as Myriad CEO (in role since April 2025, previously COO, earlier at Illumina and Agilent), on Mendelspod with Theral Timpson.
- Ambition: go from serving "a million and a half patients last year into the millions of patients" and take a business of "about $800 million in revenue this year" past a billion dollars.
- Raha says Myriad "haven't lived up to our potential" and wants it to be "iconic" in the cancer care continuum, moving beyond hereditary testing into therapy selection.
- Financial model: grow revenue at "high single digit to double digit" while growing profitability; later "we will grow in the low double digits and do that profitably".
- Pipeline at the time: expanded MyRisk panel in Q4 2025, first AI prostate test (Prolaris with PATHOMIQ) in Q1 2026, Precise MRD for low-shedding tumours starting with breast by mid-2026, FirstGene in early access.
- Reach: over 50,000 healthcare providers served in a quarter; GeneSight ran "over a half a million patient tests" last year.
- AI used for years in operations, payer denial appeals and variant classification; future reports will combine genomics, proteins and imaging.
- Biggest barriers: reimbursement cycles with US private payers, physician education ("we have a long way to go") and cost points for new technologies.

## Questions about Myriad Genetics

### What does Myriad Genetics do?

Myriad Genetics develops and sells molecular diagnostic tests that assess disease risk or progression and guide treatment, in cancer (MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, Precise MRD), mental health (GeneSight) and prenatal health, which it is selling to Labcorp.

### What is Myriad Genetics' revenue?

FY2025 revenue was $824.5 million, down 2%. FY2026 guidance is $780-$790 million.

### How many employees does Myriad Genetics have?

About 2,700 full-time equivalent employees at December 31, 2025; about 500 are expected to move to Labcorp with the Prenatal Health sale.

### Who leads Myriad Genetics?

Sam Raha has been President and CEO since April 30, 2025, with Ben Wheeler as CFO and Mark Verratti as COO.

### What is Myriad Genetics' strategy?

Accelerate profitable growth by building a comprehensive Cancer Care Continuum test menu, growing Mental Health at or above market and keeping financial and operational discipline, while exiting Prenatal Health.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
